arrow_back Back to App

US-Israel Medical Collaboration: New Drugs, Technologies, and Healthcare

This act aims to strengthen cooperation between the United States and Israel in the medical field. This means faster development of new drugs, medical technologies, and better healthcare management, which could lead to access to more modern therapies and services for citizens. The collaboration also includes the exchange of knowledge and experience, potentially improving the quality of healthcare.
Key points
Joint research on new drugs and medical technologies, including devices and digital health solutions.
Supporting innovation and startups in the health sector, which can accelerate the market introduction of new solutions.
Facilitating medical data exchange for research purposes and strengthening patient privacy protection.
Collaboration in telemedicine and digital health solutions, potentially improving access to medical care.
Joint efforts in combating infectious diseases, including vaccine development and epidemiological data exchange.
Development of biological product manufacturing, which could provide access to more affordable and available life-saving treatments.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_661
Sponsor: Rep. Buchanan, Vern [R-FL-16]
Process start date: 2025-01-23
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

MIRACLE Medical Technology Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_661.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-01-23.

What are the main provisions?

Key points include:

  • Joint research on new drugs and medical technologies, including devices and digital health solutions.
  • Supporting innovation and startups in the health sector, which can accelerate the market introduction of new solutions.
  • Facilitating medical data exchange for research purposes and strengthening patient privacy protection.
  • Collaboration in telemedicine and digital health solutions, potentially improving access to medical care.
  • Joint efforts in combating infectious diseases, including vaccine development and epidemiological data exchange.
  • Development of biological product manufacturing, which could provide access to more affordable and available life-saving treatments.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Buchanan, Vern [R-FL-16].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Public Investments